Truist Securities Reiterates Buy on Insmed, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Insmed and raised the price target from $100 to $105, indicating confidence in the company's future performance.
November 01, 2024 | 2:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on Insmed and increased the price target from $100 to $105, suggesting a positive outlook for the company's stock.
The reiteration of a Buy rating and an increase in the price target by Truist Securities indicates a positive sentiment towards Insmed's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100